Genomic Sequencing to Inform Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies

Pancreatic cancer is projected to overtake colorectal cancer to become the second most frequent cause of cancer death by 2030, with approximately 46,000 people in the US dying annually[1]. Pancreatic cancer is uniquely challenging for several reasons. In contrast to other cancers, screening has limited utility outside of rare genetic conditions[2], most cancers present at an advanced and incurable stage[3], and the latest advances in cancer therapy such as immunotherapy have not provided benefit[4,5] in unselected pancreatic cancer so far.

Source: Cancer Treatment Reviews - October 20, 2021 Category: Cancer & Oncology Authors: Nicholas Meti, Deirdre Kelly, Michael J. Allen, Ashley Lanys, Rouhi Fazelzad, Ravi Ramjeesingh, George Zogopoulos, Faiyaz Notta, Jennifer J. Knox, Eitan Amir, Steven Gallinger, Grainne O'Kane, Robert C. Grant Source Type: research